Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 15, Number 1—January 2009

Dispatch

Variation in Antimicrobial Resistance in Sporadic and Outbreak-related Salmonella enterica Serovar Typhimurium

Eva Møller NielsenComments to Author , Mia Torpdahl, Steen Ethelberg, and Anette M. Hammerum
Author affiliations: Statens Serum Institut, Copenhagen, Denmark

Main Article

Table 1

Antimicrobial resistance profile of 323 clinical Salmonella enterica serovar Typhimurium DT104 isolates, Denmark, 2003–2006*

Phenotype SGI1 genotype† Unique types, no. strains (%) All isolates, no. (%)
ACSSuT‡ SGI1§ 122 (84) 251 (78)
ACSSuTTm¶ SGI1-A 5 (3) 9 (3)
ASu SGI1-B 4 (3) 24 (7)
SSu SGI1-C 3 (2) 11 (3)
ASSuTTm SGI1-C 1 (0.7) 2 (0.6)
ASSu SGI1-B 1 (0.7) 2 (0.6)
ACST# SGI1 1 (0.7) 1 (0.3)
SSuT Not present 1 (0.7) 3 (0.9)
Sensitive
Not present
8 (6)
20 (6)
Total 146 (100) 323 (100)

*One isolate per multilocus variable number of tandem repeats analysis (MLVA) and antimicrobial resistance profile is represented in the data set of 146 strains with unique types. A, ampicillin; C, chloramphenicol; S, streptomycin; Su, sulfonamides; T, tetracycline; Tm, trimethoprim.
†SGI, Salmonella genomic island. Genotype determined by the SGI1-related PCR assays described in the text (1 isolate per “unique type”); see Table 2 for selected details.
‡Additional antimicrobial-drug resistances: nalidixic acid and ciprofloxacin (22 strains), amoxicillin/clavulanic acid (3 strains), gentamicin (1 strain).
§Only a small subset of 10 ACSSuT strains was tested by PCR for the presence of SGI1 genes.
¶Additional antimicrobial-drug resistances: nalidixic acid, ciprofloxacin, and gentamicin (1 strain).
#Additional antimicrobial-drug resistances: nalidixic acid and ciprofloxacin.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO